ausblenden:
Schlagwörter:
-
Zusammenfassung:
Metabolomic analyses in epidemiological studies have demonstrated a
strong sexual dimorphism for most metabolites. Cross-sex hormone
treatment (CSH) in transgender individuals enables the study of
metabolites in a cross-gender setting. Targeted metabolomic profiling of
serum of fasting transmen and transwomen at baseline and following 12
months of CSH (N = 20/group) was performed. Changes in 186 serum
metabolites and metabolite ratios were determined by targeted
metabolomics analysis based on ESI-LC-MS/MS. RandomForest (RF) analysis
was applied to detect metabolites of highest interest for grouping of
transwomen and transmen before and after initiation of CSH. Principal
component analysis (PCA) was performed to check whether group
differentiation was achievable according to these variables and to see
if changes in metabolite levels could be explained by a priori gender
differences. PCA predicted grouping of individuals-determined by the
citrulline/arginine-ratio and the amino acids lysine, alanine and
asymmetric dimethylarginine - in addition to the expected grouping due
to changes in sex steroids and body composition. The fact that most of
the investigated metabolites did, however, not change, indicates that
the majority of sex dependent differences in metabolites reported in the
literature before may primarily not be attributable to sex hormones but
to other gender-differences.
